Research Reports

Key takeaways

Revenue was $25.6M (-8.0% YoY), driven by timing adjustments in royalty recognition under the Jemperli Royalty Monetization Agreement with Sagard, not lower underlying sales.

Operating income was -$34.6M (-25.8% YoY), with operating margin at -135.5%, underscoring that revenue does not cover core operating costs in this transitional period.

Net income was -$52.9M (-34.5% YoY) and diluted EPS was $-1.84 (-43.8% YoY), consistent with the GAAP treatment of non-cash interest expense tied to Jemperli sales performance.

Net cash used in operating activities was -$25.9M (vs. -$10.7M prior year), reflecting the net loss and absence of material non-cash addbacks supported by authoritative disclosure.

Capital expenditures were $17,000 (vs. $35,000 prior year), indicating minimal investment in long-lived assets during the quarter.

Free cash flow was -$25.9M, calculated as operating cash flow minus capital expenditures, per the filing’s defined methodology.

Full analysis

Revenue

Revenue decreased 8.0% year-over-year to $25.6M, entirely attributable to collaboration revenue from the Jemperli Royalty Monetization Agreement with Sagard. As stated in the filing, this decline reflects 'an increase in the GSK Jemperli sales which changed the expected timing for Sagard to be paid' — a dynamic that shifts revenue recognition under the effective interest method. Higher underlying commercial performance accelerated the amortization of the liability, increasing non-cash interest expense and reducing the portion of future royalties allocated to the current period. The filing confirms: 'We have not generated any revenue from product sales,' reinforcing that all revenue remains royalty-based and subject to this accounting interdependence.

Operating and Net Loss

Cash Flow and Capital Use

Strategic Context

The quarter occurred amid financial and operational transition following the separation from First Tracks Biotherapeutics. Management states that post-spin-off capital use focuses on public company costs, legal and audit services, consulting, insurance, and transition services — not R&D or manufacturing. While the filing notes that 'it is possible we may need to raise capital in the future,' it does not quantify near-term liquidity, forecast runway, or balance sheet obligations, and no such figures appear in the authoritative financial packet.